losartan has been researched along with Day Blindness in 2 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan is an inhibitor of transforming growth factor-β signaling." | 5.72 | Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience. ( Ambrósio, R; Bandeira, F; Pereira-Souza, AL; Salomão, MQ; Souza Lima, A; Wilson, SE, 2022) |
| "Losartan is an inhibitor of transforming growth factor-β signaling." | 1.72 | Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience. ( Ambrósio, R; Bandeira, F; Pereira-Souza, AL; Salomão, MQ; Souza Lima, A; Wilson, SE, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pereira-Souza, AL | 1 |
| Ambrósio, R | 1 |
| Bandeira, F | 1 |
| Salomão, MQ | 1 |
| Souza Lima, A | 1 |
| Wilson, SE | 1 |
| Lehnhardt, A | 1 |
| Lama, A | 1 |
| Amann, K | 1 |
| Matejas, V | 1 |
| Zenker, M | 1 |
| Kemper, MJ | 1 |
2 other studies available for losartan and Day Blindness
| Article | Year |
|---|---|
Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience.
Topics: Adult; Corneal Diseases; Corneal Opacity; Corneal Stroma; Female; Fibrosis; Humans; Keratomileusis, | 2022 |
Pierson syndrome in an adolescent girl with nephrotic range proteinuria but a normal GFR.
Topics: Abnormalities, Multiple; Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting | 2012 |